Filters

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018;20(6):679-686

Full Text

Abstract

Alpha and Beta Radiation for Theragnostics.

Hong Song, George Sgouros

PET clinics 2024;19(3):307-323

Full Text

Abstract

Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.

Daniel P Petrylak, Philippa J Cheetham

Oncology (Williston Park, N.Y.) 2012;26(4):330-7, 341

Full Text

Abstract

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.

Homer A Macapinlac, Eric M Rohren, Elba Etchebehere, Denai R Milton, Kalevi Kairemo

Current radiopharmaceuticals 2018;11(2):147-152

Full Text

Abstract

Clinical dosimetry in the treatment of bone tumors: old and new agents.

C Hindorf, G D Flux, C Ibisch, F Kraeber Bodéré

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 2011;55(2):198-204

Full Text

Abstract

Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatments.

Hance Clarke, Enrique Soto-Perez-de-Celis, Henriette Breunis, Urban Emmenegger, Aaron Hansen, Milothy Parthipan, Gregory Feng, Narhari Timilshina, Andrew Matthew, George Tomlinson, Daniel Santa Mina, Shabbir M H Alibhai, Martine Puts

Journal of geriatric oncology 2024;15(3):101720

Free Full Text

Abstract

Results: 1 – 15 / 33

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Radium""[mesh_terms]

Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results.

Tracing the Evolution of Prostate Brachytherapy in the 20th Century.

Study of soil-plant transfer of 226Ra under greenhouse conditions.

Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium.

Therapy assessment of bone metastatic disease in the era of radium.

State of the art and future perspectives of new radinuclides in Nuclear Medicine: Part III.

Soil-to-root vegetable transfer factors for (226)Ra, (232)Th, (40)K, and (88)Y in Malaysia.

Radium-223 for Metastatic Castrate-Resistant Prostate Cancer.

Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns.

Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.

Alpha and Beta Radiation for Theragnostics.

Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.

Clinical dosimetry in the treatment of bone tumors: old and new agents.

Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatments.

Results for
""Radium""[mesh_terms]